Effect of Hepatic Impairment on the Pharmacokinetics of Single-Dose Viloxazine Extended-Release Capsules (Qelbree®) in Adults Authors: Zhao Wang, Toyin Adewole, Lilian W Adeojo, Peibing Qin, Stefan Schwabe, Azmi Nasser Published: 2026 ABSTRACT AbstractBackground and ObjectivesViloxazine (extended-release [ER] capsules) is a nonstimulant medication approved for the treatment of pediatric (aged ≥ 6 years) and adult attention deficit hyperactivity disorder. This study assessed the effect of hepatic impairment (HI) on the pharmacokinetics, safety, and tolerability of viloxazine ER.MethodsIn this open-label, multicenter study, adults (18–78 years) with mild (n = 8), moderate (n = 8), or severe (n = 8) HI (Child–Pugh classification) and a demographically matched control cohort with normal hepatic function received a single oral dose of viloxazine ER (200 or 400 mg), following a ≥ 10-h overnight fast. Blood samples were collected for 72 h post-administration and analyzed for viloxazine and its primary metabolite 5-hydroxy-viloxazine glucuronide. The potential for HI to impact pharmacokinetics was evaluated using relative bioavailability analysis of viloxazine maximum measured plasma concentration (Cmax) and area under the concentration–time curve (AUC) parameters and comparison of time to Cmax (Tmax) and terminal elimination half-life (t1/2). Safety and tolerability were also evaluated.ResultsIn adults with versus without HI (any severity), there were no significant differences in viloxazine Cmax (mean ± standard deviation [SD] for mild HI, 3.1 ± 1.0 µg/mL versus 2.4 ± 0.4 µg/mL; moderate HI, 2.5 ± 0.8 µg/mL versus 2.5 ± 0.6 µg/mL; severe HI, 1.3 ± 0.4 µg/mL versus 1.5 ± 0.2 µg/mL) and AUC (from time 0 to infinity; mean ± SD for mild HI, 70.5 ± 19.3 h·µg/mL versus 56.8 ± 8.6 h·µg/mL; moderate HI, 62.8 ± 28.9 h·µg/mL versus 60.4 ± 20.5 h·µg/mL; severe HI, 42.0 ± 16.4 h·µg/mL versus 33.1 ± 9.7 h·µg/mL), and mean exposure for those with HI was within 25% of matched control values. Increased t1/2 was observed in moderate and severe HI versus controls (mean ± SD for mild HI, 7.6 ± 3.1 h versus 6.7 ± 2.5 h; moderate HI, 9.3 ± 3.1 h versus 6.0 ± 1.7 h; severe HI, 14.2 ± 5.8 h versus 7.1 ± 2.7 h). No adverse event (AE) was reported by ≥ 2 study participants with HI. The most common AEs were headache (n = 1 mild HI, n = 2 healthy controls) and somnolence (n = 2 healthy controls).ConclusionsMild-to-severe HI showed minimal impact on viloxazine ER exposure. The single dose of viloxazine ER was well-tolerated with no identified safety concerns.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s40261-026-01580-w. Key Points After receiving a single dose of viloxazine extended release, modest differences in some pharmacokinetic parameters were observed between individuals with and without hepatic impairment.Average viloxazine exposure in individuals with mild, moderate, or severe hepatic impairment was within 25% of the viloxazine exposure in individuals without hepatic impairment.The impact of hepatic impairment on the pharmacokinetic profile and bioavailability of viloxazine does not warrant blanket recommendations for dosage adjustment. Introduction Viloxazine extended-release (ER) capsules (Qelbree® [Supernus Pharmaceuticals, Inc.; Rockville, MD, USA]) are a nonstimulant, Food and Drug Administration (FDA)-approved treatment for attention deficit hyperactivity disorder (ADHD) in pediatrics (≥ 6 years) and adults. Viloxazine ER is pharmacologically distinct from other ADHD medications, showing norepinephrine transport inhibition, 5HT2c partial agonism, and 5HT2b and 5HT7 antagonism at clinically administered doses [1–5]. The role of these pharmacodynamic effects in mediating therapeutic effects is unclear, and translational implications in humans remain to be fully elucidated [3]. Viloxazine is rapidly and almost completely absorbed following oral administration [6]. The ER dosage form prolongs absorption by controlling the rate of drug release, allowing once-daily dosing while also minimizing peak-to-trough fluctuations in plasma concentrations that could potentially affect tolerability. Viloxazine is primarily metabolized via 5-hydroxylation and subsequent glucuronidation. Hydroxylation is principally mediated by the hepatic isoenzyme cytochrome P450 (CYP) 2D6, with minor contributions from CYP1A2, 2B6, 2C9, 2C19, and 3A4 [7]. Subsequent glucuronidation of the 5-hydroxy-viloxazine (5-HVLX) metabolite to 5-HVLX-glucuronide (5-HVLX-gluc) is mediated by uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A9 and 2B15. Renal excretion is the primary elimination pathway, with ~ 22% of a viloxazine dose excreted unchanged in the urine [7] and < 1% elimination in feces [5]. Despite CYP2D6 serving as a primary metabolic pathway, this enzyme accounts for < 50% of total metabolism [8], and lack of functional CYP2D6 enzyme availability due to genetic polymorphism or pharmacologic inhibition does not meaningfully affect viloxazine pharmacokinetics, perhaps owing to the ability of other pathways to accommodate metabolism [9]. For example, co-administration of viloxazine ER with paroxetine (a strong CYP2D6 inhibitor) modestly increased viloxazine plasma concentrations (< 35% increase in area under the plasma concentration–time curve [AUC] and had no effect on maximum plasma concentrations [Cmax]) [8]. Likewise, administration to CYP2D6 poor metabolizers only modestly increased viloxazine systemic exposure (~20% increase in Cmax and 25% increase in AUC) [9]. With respect to the ability of viloxazine to affect hepatic enzyme metabolic pathways, both in vitro studies using human hepatic microsomes and human drug–drug interaction studies using index substrates have shown viloxazine to be a strong inhibitor of CYP1A2 and a weak inhibitor of CYP2D6 and CYP3A4 [7, 9]. For example, when co-administered with single doses of caffeine (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), and midazolam (CYP3A4 substrate), viloxazine substantially increased caffeine total exposure (~ 4.4–5.8-fold increase in AUC) without affecting the maximum exposure (Cmax, 90% confidence interval [CI] 95.8–102.5), and modestly increased dextromethorphan (1.9-fold increase in AUC) and midazolam (1.7-fold increase in AUC) exposure [9]. Additional studies in healthy adults have shown a lack of significant drug–drug interactions between viloxazine ER and the stimulant medications methylphenidate [10] and lisdexamfetamine [11] and a lack of meaningful effect of the CYP2D6 inhibitor paroxetine on viloxazine ER exposure [8]. Renal and hepatic impairment may alter drug pharmacokinetics, potentially necessitating dose adjustments to maintain safety and efficacy [12]. The objectives of this phase 1 study were to assess the effects of mild, moderate, or severe hepatic impairment on the pharmacokinetic profile and relative bioavailability of viloxazine ER, and secondly, to evaluate the safety and tolerability of viloxazine ER in individuals with hepatic impairment. Methods Study Design Overview This study was approved by IntegReview Institutional Review Board (Austin, TX, USA) and conducted in accordance with the Helsinki Declaration and the International Council for Harmonisation Good Clinical Practice Guidelines. Participants were recruited by study sites through local advertisements. All participants provided written informed consent and were compensated for their time spent participating in the study. The trial was conducted at four study centers: Worldwide Clinical Trials, Early Phase Services, LLC (San Antonio, TX, USA), Orlando Clinical Research Center (Orlando, FL, USA), Clinical Pharmacology of Miami, LLC (Miami, FL, USA), and Advanced Pharma CR, LLC (Miami, FL, USA). Participants and Study Design This open-label, multicenter, parallel-group, single-dose study recruited up to eight participants each with mild, moderate, and severe hepatic impairment, and healthy control participants with normal hepatic function. Healthy control groups for mild and moderate hepatic impairment included eight participants; the control group for severe hepatic impairment included seven participants. Mild, moderate, and severe hepatic impairment correspond to Child–Pugh class A, B, and C, respectively, with Child–Pugh scores based on both clinical and biochemical criteria, including presence and severity of encephalopathy and ascites, elevations in serum bilirubin, reduction in albumin, and prolongation of prothrombin time or international normalized ratio. Participants were between 18 years and 78 years of age and with body mass index (BMI) of 18–40 kg/m2 (inclusive). Healthy controls were demographically matched to (one or more) individuals with hepatic impairment for sex, age (approximately ± 10 years), and BMI (approximately ± 20%). Individuals with significant (unmanaged) medical conditions, human immunodeficiency virus (HIV) infection, current alcohol abuse (within 1 year of screening) or drug abuse, were pregnant or lactating, or had other conditions that could interfere with study participation were ineligible. Because viloxazine ER is a strong CYP1A2 inhibitor, participants were excluded if they had taken any CYP1A2 substrate medications within 30 days or five half-lives, whichever is longer, before dosing. Participants were also excluded if they had any acute or significant illness within 14 days prior to dosing (as judged by the investigator). Participants with hepatic impairment were to be generally healthy (other than conditions consistent with hepatic failure or associated symptoms), with no clinically significant change in disease status within 30 days prior to screening. Participants with severe hepatic impairment could not have grade 4 encephalopathy. Individuals who were positive for hepatitis C antibody were eligible for the study if they had no viral load from quantitative hepatitis C RNA testing. Individuals with diabetes were considered eligible if their estimated glomerular filtration rate (eGFR) was greater than or equal to 60 mL/min/1.73 m2. Individuals who smoked cigarettes had to be willing to reduce to ≤ 5 per day from the time of admission to last pharmacokinetic sampling. Healthy control participants were required to have normal hepatic function, without positive screen for hepatitis B or C, and to have not used prescription, herbal, or systemic over-the-counter medications (other than acetaminophen [< 2 g/day] or hormonal replacement or birth control) within 14 days of study entry or medications known to induce or inhibit hepatic metabolism within 30 days of screening. Healthy controls were also required to abstain from tobacco use beginning 7 days prior to study entry through last sample collection in the study. All participants were to abstain from consuming alcohol, food, or beverages containing xanthine (caffeine) or related compounds, energy drinks, grapefruit, pomelo, garlic supplements, or poppy seeds beginning 48 h prior to dosing until after the last sample collection in the study. Within 28 days of initial screening, participants presented to the study unit (day − 1; entry day) to confirm eligibility. Enrolled participants were then admitted to the clinic for the duration of study conduct. Following an overnight fast of at least 10 h, participants received a single dose of oral viloxazine ER (doses below) administered with 240 mL of room temperature water. Fasting continued for 4 h following dosing, and other than the water administered with dosing, fluids were restricted 1 h before and after to minimize absorption variability. Blood draws (4 mL each) for the determination of viloxazine and 5-HVLX-gluc concentrations were collected pre-dose (0 h), and 0.5, 1, 2, 3, 4, 5, 7, 9, 12, 24, 36, 48, and 72 h post-dose. End-of-study procedures were conducted at 72 h following dosing or upon early withdrawal. Treatments Participants with mild (group 1) and moderate (group 2) hepatic impairment received a single dose of viloxazine ER 400 mg orally, and participants with severe hepatic impairment (group 3) received a single dose of viloxazine ER 200 mg orally. Healthy controls (group 4) received the same dose of viloxazine ER as the participant with whom they were matched (i.e., 200 mg or 400 mg). To ensure safety for participants with severe hepatic impairment, ten participants with mild or moderate hepatic impairment were dosed first. Upon review of these patients’ pharmacokinetic profiles, 200 mg viloxazine ER was selected for the severe hepatic impairment group to be conservative. When not fasting, participants ate standard meals, including breakfast, a low-fat lunch (< 30% fat), an evening meal, and a snack (all provided at the appropriate time intervals). Decaffeinated coffee or tea (as xanthine-containing beverages) were not allowed. Participants were allowed free access to drinking water from 1 h after dosing. Sample Collection Timing of blood sample collection is described above. The actual time and date of each blood sample collection was recorded. If deemed necessary by the investigator, a catheter was inserted into the arm as an alternative to repeated venipunctures. Blood samples were collected in a 4 mL K2-EDTA (purple top) tube and gently inverted eight to ten times. Within 30 min of blood collection, samples were then centrifuged at 3000 rpm for 10 min at approximately 4 ºC. The resulting plasma was aliquoted in approximately equal amounts into two 3-mL polypropylene screw-cap tubes. Within 60 min of blood collection, samples were frozen in an upright position at − 70 ºC until analysis. Endpoints, Bioanalytical Methods, and Pharmacokinetic Analyses The primary endpoints were (1) to assess viloxazine pharmacokinetic parameters using noncompartmental analyses in individuals with mild, moderate, and severe hepatic impairment relative to healthy controls, including area under the concentration–time curve (AUC) from time 0 to the last measurable concentration time (AUC0–t), AUC from time 0 to infinity (AUCinf), maximum observed plasma concentration (Cmax), time to maximum concentration (Tmax), and terminal elimination half-life (t1/2), and (2) to evaluate the relationship between viloxazine peak and total exposures (Cmax and AUC, respectively) and the hepatic function based on Child–Pugh classification (i.e., bilirubin, albumin, prothrombin time, and international normalized ratio [INR]). The pharmacokinetic parameters included in the primary endpoints were selected because these parameters are most directly related to drug peak and total exposures and relative bioavailability. Secondary endpoints were to evaluate viloxazine ER pharmacokinetic parameters of apparent volume of distribution (Vd/F), apparent total body clearance (CL/F), the percentage of AUCinf based on extrapolation (AUCextrap%), and terminal elimination rate constant estimated by log-linear regression (lambda-z [λz]) relative to healthy controls; the pharmacokinetics of the 5-HVLX-gluc metabolite relative to healthy controls; 5-HVLX-gluc-to-viloxazine (metabolite-to-parent) ratios for AUC0–t, AUCinf, and Cmax; and safety in individuals with hepatic impairment as measured by adverse events, clinical laboratory tests, vital signs, electrocardiograms (ECGs), and physical examination. Plasma concentrations of viloxazine and 5-HVLX-gluc were quantified using validated ultraperformance liquid chromatography–tandem mass spectrometry assays performed on a Waters Quattro Premier XE or Waters Xevo TQ-S micro mass spectrometer (Waters Corporation, Milford, MA, USA), as previously described [10, 11]. For viloxazine, a 50-μL plasma sample was spiked with viloxazine-d5 as an internal standard and extracted through supported liquid extraction. Chromatographic separation was achieved on an Acquity UPLC BEH C8 1.7 μm, 2.1 mm × 50 mm column (Waters Corporation) using 10 mM ammonium bicarbonate (pH 9.0) and acetonitrile mobile phases with a gradient program. Detection was performed using positive electrospray ionization and multiple reaction monitoring for precursor → product transitions (m/z) of 238 → 100 for viloxazine and 243 → 56 for viloxazine-d5. The assay was validated from 0.0100 μg/mL (lower limit of quantification [LLOQ]) to 10.0 μg/mL (upper limit of quantification [ULOQ]), with inter- and intra-run precision (relative standard deviations) of ≤ 9% and ≤ 10%, respectively, and intra-run accuracy of 97–107%. For 5-HVLX-gluc, a 100-μL plasma sample was spiked with 5-HVLX-gluc-d5 as an internal standard and extracted by mixed-mode cation exchange solid-phase extraction. Chromatographic separation was achieved on a Pinnacle DB Biphenyl 1.9 μm, 2.1 mm × 50 mm column (Restek Corporation, Bellefonte, PA, USA) using 0.1% formic acid in water and methanol mobile phases with an isocratic program. Detection was performed using positive electrospray ionization and multiple reaction monitoring for precursor → product transitions (m/z) of 430 → 254 for 5-HVLX-gluc and 435 → 259 for 5‑HVLX-gluc-d5. The assay was validated from 0.00500 μg/mL (LLOQ) to 10.0 μg/mL (ULOQ), with inter- and intra-run precision (relative standard deviations) of ≤ 14% and intra-run accuracy of 94–115%. The safety analysis population included all participants who received any dose of viloxazine ER. The pharmacokinetic analysis population included all participants from the safety population who had viloxazine and/or 5-HVLX plasma concentrations that were adequate to derive pertinent pharmacokinetic parameters and no major events with the potential to impact the pharmacokinetic data. The concentration–time data for viloxazine and 5-HVLX-gluc were analyzed using standard noncompartmental methods in Phoenix™ WinNonlin® (version 8.1; Certara, L.P.; Radnor, PA, USA) in conjunction with the internet-accessible implementation of Pharsight® Knowledgebase ServerTM (PKSO; version 4.0.4; Certara, L.P.). Viloxazine and 5-HVLX-gluc plasma concentrations below the LLOQ (BLQ) were treated as zero from dosing (t0) until the first time point with a quantifiable concentration; all embedded and terminal values that were BLQ were treated as missing. Pharmacokinetic and statistical analyses relied on the actual sample collection times. Pharmacokinetic results were summarized by analyte, hepatic impairment group, and viloxazine ER dose using descriptive statistics (arithmetic mean, standard deviation [SD], median, coefficient of variation [CV], geometric mean, and geometric mean CV). Geometric means were used for bioavailability calculations. Metabolite-to-parent ratios were adjusted according to the molecular weights of viloxazine (237 g/mol) and 5-HVLX-gluc (429 g/mol). The elimination rate constant (Kel) was reported only when at least three quantifiable concentrations were used in the regression, the Cmax or data before the Cmax were not included in the regression, and the adjusted regression coefficient (R2 adj) was ≥ 0.80. AUCinf was only reported if the extrapolated percentage was < 20%. Safety assessments and clinical laboratory analyses were performed by the principal investigator at Worldwide Clinical Trials Early Phase Services, LLC. Statistical Analyses The impact of hepatic impairment on viloxazine ER bioavailability and metabolism was evaluated using analysis of variance (ANOVA) on viloxazine and 5-HVLX-gluc log-transformed pharmacokinetic parameters Cmax, AUC0–t, and AUCinf, using group and dose as independent fixed effects. Each hepatic impairment severity group was compared with their respective healthy control group from one ANOVA for multiple group comparison. Healthy control participants could be matched to multiple participants in the hepatic impairment groups. Ratios for Cmax, AUC0–t, and AUCinf were calculated as the geometric mean (hepatic impairment group)/geometric mean (respective healthy control group) and are reported with 90% confidence intervals (CIs). Nonparametric Wilcoxon rank-sum tests between participants with hepatic impairment and normal hepatic function were performed on Tmax and t1/2 using untransformed data. For ANOVA and Wilcoxon rank-sum tests, significant differences were defined a priori as p < 0.05. Concentration–time profiles are plotted as means ± SD. Box plots were created for viloxazine and 5-HVLX-gluc to compare Cmax, AUC0–t, and AUCinf across each group of patients with hepatic impairment and their respective control groups, with pharmacokinetic parameter (Cmax and AUC) values scaled to the 400-mg dose for participants receiving doses of 200 mg (i.e., severe hepatic impairment and matched controls). The relationships between dose-adjusted pharmacokinetic parameters and hepatic function were explored by performing a regression analysis, plotting respective hepatic function parameters on the x-axis and pharmacokinetic parameters on the y-axis. Safety and tolerability data were summarized descriptively. Results Participant Demographics The study included 45 adult participants (31 male, 14 female; mean ± SD age 59.8 ± 8.7 years; age range 42–77 years). Participants’ BMI was (mean ± SD) 29.7 ± 4.3 kg/m2; 91.1% were white, and 8.9% were Black or African American. Participant demographics by hepatic function group assignment are listed in Supplementary Table S1. Relevant laboratory parameters considered for evaluating Child–Pugh score are listed in Supplementary Table S2. All 45 participants received viloxazine ER and completed the study. One participant from group 1 (mild hepatic impairment) was dosed in error and was retained in the safety population (n = 45) but excluded from the pharmacokinetic population (n = 44). Impact of Hepatic Impairment on Viloxazine Pharmacokinetics and Bioavailability Viloxazine pharmacokinetic parameters for each group (mild, moderate, and severe hepatic impairment and matched healthy controls) are listed in Table 1, and respective plasma concentration–time curves are shown in Fig. 1. Tmax was not statistically significantly different from matched healthy control groups for participants with mild or moderate hepatic impairment (p = 0.37 and p = 0.52, respectively) but was prolonged in patients with severe impairment (median 9 h) relative to matched healthy controls (4 h; p = 0.0164). The mean t1/2 of viloxazine ER was also significantly prolonged in moderate (9.3 h) and severe (14.2 h) hepatic impairment relative to their matched healthy control groups (6.0 h [p = 0.0480] and 7.1 h [p = 0.0325], respectively). Despite these changes, hepatic impairment had only modest impact on viloxazine peak and total exposures, with mean Cmax decreasing by ~15% and mean AUC increasing by ~ 25% in participants with severe hepatic impairment relative to healthy controls based on least-squares geometric mean ratios (LSGMRs); these differences were not significant based on ANOVA (Table 2 and Fig. 2). Table 1Summary of viloxazine plasma pharmacokinetic parametersParameterGroup 1Mild HIa (n = 8)Group 4aHealthy matcha (n = 8)P valueGroup 2Moderate HIa (n = 8)Group 4bHealthy matcha (n = 8)P valueGroup 3Severe HIb (n = 8)Group 4cHealthy matchb (n = 7)P valueTmax (h)7.0 (3.0–9.0)5.0 (4.0–7.0) 0.37066.0 (4.0–9.0)5.0 (4.0–9.0) 0.52169.0 (5.0–12.0)4.0 (4.0–7.0) 0.0164Cmax (µg/mL)3.1 ± 1.0 (31.3%)2.4 ± 0.4 (17.4%)0.12082.5 ± 0.8 (31.0%)2.5 ± 0.6 (22.9%)0.67781.3 ± 0.4 (31.1%)1.5 ± 0.2 (14.0%)0.2631AUC0–t (h·µg/mL)69.2 ± 19.2 (27.7%)55.8 ± 9.0 (16.1%)0.272760.2 ± 28.1 (46.6%)59.3 ± 19.0 (32.0%)0.726339.2 ± 13.1 (33.3%)31.7 ± 9.5 (29.9%)0.2434AUCinf (h·µg/mL)70.5 ± 19.3 (27.4%)56.8 ± 8.6 (15.2%)0.276062.8 ± 28.9 (46.0%)60.4 ± 20.5 (34.0%)0.863142.0 ± 16.4 (38.9%)33.1 ± 9.7 (29.3%)0.2341t1/2 (h)7.6 ± 3.1 (40.3%)6.7 ± 2.5 (36.8%) 0.71839.3 ± 3.1 (33.1%)6.0 ± 1.7 (28.5%) 0.048014.2 ± 5.8 (41.0%)7.1 ± 2.7 (37.1%) 0.0325CL/F (mL/min)101 ± 25.9 (25.8%)120 ± 16.7 (13.9%)Not done138 ± 96.1 (69.6%)119 ± 31.9 (26.7%)Not done89.9 ± 32.6 (36.3%)111 ± 43.3 (39.0%)Not doneVd/F (L)67.0 ± 37.5 (55.9%)70.2 ± 28.8 (41.0%)Not done106 ± 68.2 (64.4%)59.0 ± 13.8 (23.4%)Not done97.6 ± 19.1 (19.5%)65.5 ± 22.7 (34.7%)Not doneAll data reported as mean ± SD (CV), except Tmax, which is reported as median (range)AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, CL/F apparent total body clearance after oral administration, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, h hours, HI hepatic impairment, SD standard deviation, t1/2 terminal elimination half-life, Tmax time of the maximum measured plasma concentration, Vd/F apparent volume of distribution after oral administrationP values for Tmax and t1/2 are from nonparametric Wilcoxon rank-sum tests on untransformed parameter valuesP values for Cmax, AUC0–t, and AUCinf are from analysis of variance analyses of log-transformed parameter valuesaSingle-dose viloxazine ER (400 mg)bSingle-dose viloxazine ER (200 mg) Summary of viloxazine plasma pharmacokinetic parameters All data reported as mean ± SD (CV), except Tmax, which is reported as median (range) AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, CL/F apparent total body clearance after oral administration, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, h hours, HI hepatic impairment, SD standard deviation, t1/2 terminal elimination half-life, Tmax time of the maximum measured plasma concentration, Vd/F apparent volume of distribution after oral administration P values for Tmax and t1/2 are from nonparametric Wilcoxon rank-sum tests on untransformed parameter values P values for Cmax, AUC0–t, and AUCinf are from analysis of variance analyses of log-transformed parameter values aSingle-dose viloxazine ER (400 mg) bSingle-dose viloxazine ER (200 mg) Viloxazine concentration–time profiles. Viloxazine concentration–time profiles after administration of viloxazine ER in participants with mild, moderate, or severe HI (groups 1, 2, and 3) and healthy matches (groups 4a, 4b, and 4c) on linear (A, C, E) and semi-logarithmic (B, D, F) scales. Participants with mild or moderate HI and healthy matches received viloxazine ER 400 mg. Participants with severe HI and healthy matches received viloxazine ER 200 mg. Means ± standard deviation. ER extended release, HI hepatic impairment Table 2Viloxazine relative bioavailabilityHIHealthy matchRatio (90% CI)dCVCmax Milda2.942.38123.69% (98.94–154.64)25.8% Moderateb2.332.4694.54% (72.06–124.03)31.6% Severec1.251.4685.42% (68.81–106.03)23.9%AUC0–t Milda66.955.3121.02% (99.47–147.23)22.5% Moderateb53.757.194.13% (64.12–138.20)45.8% Severec37.430.3123.39% (90.65–167.97)34.6%AUCinf Milda68.356.3121.39% (100.38–146.79)21.8% Moderateb56.257.997.00% (65.85–142.88)46.2% Severec39.431.7124.54% (89.45–173.39)37.3%All values are the geometric means, based on least-squares means of log-transformed parameter valuesAUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, CI confidence interval, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, HI hepatic impairmentaCompares group 1 (mild HI) versus matched controls, single-dose viloxazine ER (400 mg)bCompares group 2 (moderate HI) versus matched controls, single-dose viloxazine ER (400 mg)cCompares group 3 (severe HI) versus matched controls, single-dose viloxazine ER (200 mg)dRatio = HI/healthy matches (%), with 90% CIs Viloxazine relative bioavailability All values are the geometric means, based on least-squares means of log-transformed parameter values AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, CI confidence interval, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, HI hepatic impairment aCompares group 1 (mild HI) versus matched controls, single-dose viloxazine ER (400 mg) bCompares group 2 (moderate HI) versus matched controls, single-dose viloxazine ER (400 mg) cCompares group 3 (severe HI) versus matched controls, single-dose viloxazine ER (200 mg) dRatio = HI/healthy matches (%), with 90% CIs Relative bioavailability of plasma viloxazine. Ratio (%) of the relative bioavailability of viloxazine in plasma for PK parameters Cmax (A), AUC0–t (B), and AUCinf (C; geometric means ± 90% confidence intervals, based on least-squares means of log-transformed parameter values). AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, PK pharmacokinetic Impact of Hepatic Impairment on 5-HVLX-gluc Pharmacokinetics and Bioavailability Pharmacokinetic parameters for viloxazine’s primary metabolite 5-HVLX-gluc are listed in Table 3, and plasma concentrations over time are shown in Fig. 3. The Tmax values for the metabolite were not statistically different from matched healthy controls in the mild and moderate hepatic impairment groups but were more prolonged in the severe impairment group (median 12.0 h versus 9.0 h in matched healthy controls) where between-group difference approached statistical significance (p = 0.06). Likewise, though not significantly different in mild and moderate hepatic impairment, the mean 5-HVLX-gluc t1/2 was significantly prolonged in participants with severe hepatic impairment relative to matched healthy controls, with mean values of 11.8 h versus 6.0 h, respectively, p = 0.007. Similarly, mean metabolite-to-parent ratios for Cmax and AUC values were comparable for participants with mild and moderate hepatic impairment relative to matched healthy controls but showed modest reductions (lower metabolite levels as a percentage of parent drug) for participants with severe hepatic impairment (Table 3). LSGMRs for Cmax and AUC values showed progressively reduced exposure to the 5-HVLX-gluc metabolite in participants with moderate and severe hepatic impairment relative to matched healthy controls, with LSGMR for Cmax ~ 50% of healthy controls and AUC values ~70% of matched controls for severe hepatic impairment (Table 4 and Fig. 4). Table 3Summary of 5-HVLX-gluc plasma pharmacokinetic parametersParameterMild HIa (n = 8)Healthy matcha (n = 8)P valueModerate HIa (n = 8)Healthy matcha (n = 8)P valueSevere HIb (n = 8)Healthy matchb (n = 7)P valueTmax (h)9.0 (7.0–9.0)9.0 (5.0–12.0) 1.00009.0 (5.0–12.0)7.0 (4.0–12.0) 0.331812.0 (9.0–24.0)9.0 (5.0–12.0) 0.0612Cmax (µg/mL)2.4 ± 0.7 (31.8%)2.1 ± 1.0 (45.7%)0.39531.3 ± 0.5 (39.4%)1.6 ± 0.5 (28.9%)0.11440.39 ± 0.14 (36.7%)0.73 ± 0.1 (10.9%)0.0003AUC0–t (h·µg/mL)52.0 ± 13.9 (26.8%)48.0 ± 19.4 (40.3%)0.463129.9 ± 11.2 (37.6%)36.3 ± 12.1 (33.2%)0.212611.9 ± 3.3 (27.9%)17.0 ± 3.2 (18.6%)0.0293AUCinf (h·µg/mL)52.8 ± 14.3 (27.0%)48.5 ± 19.3 (39.9%)0.455630.8 ± 12.7 (41.3%)37.0 ± 12.3 (33.3%)0.224112.4 ± 3.5 (28.2%)17.1 ± 3.1 (18.2%)0.0444t1/2 (h)8.0 ± 1.3 (16.0%)6.9 ± 1.4 (19.6%) 0.14867.9 ± 3.1 (39.5%)7.2 ± 1.2 (17.2%) 0.643311.8 ± 3.1 (26.3%)6.0 ± 1.1 (17.8%) 0.0066Metabolite-to-parent (5-HVLX-gluc to viloxazine) ratiosc MPR Cmax0.46 ± 0.19 (41.8%)0.48 ± 0.16 (33.0%)Not done0.34 ± 0.25 (73.6%)0.37 ± 0.15 (39.9%)Not done0.18 ± 0.09 (48.4%)0.28 ± 0.05 (17.7%)Not done MPR AUC0–t0.46 ± 0.20 (44.7%)0.48 ± 0.20 (41.1%)Not done0.39 ± 0.35 (90.3%)0.37 ± 0.17 (46.2%)Not done0.19 ± 0.10 (52.2%)0.31 ± 0.08 (25.8%)Not done MPR AUCinf0.46 ± 0.21 (45.8%)0.48 ± 0.20 (41.0%)Not done0.38 ± 0.35 (91.6%)0.37 ± 0.17 (46.3%)Not done0.18 ± 0.10 (53.6%)0.30 ± 0.07 (24.7%)Not doneAll data reported as mean ± SD (CV), except Tmax, which is reported as median (range)P values for Tmax and t1/2 are from nonparametric Wilcoxon rank-sum tests on untransformed parameter valuesP values for Cmax, AUC0–t, and AUCinf are from analysis of variance analyses of log-transformed parameter values5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, h hours, HI hepatic impairment, MPR metabolite-to-parent ratio, SD standard deviation, t1/2 terminal elimination half-life, Tmax time of the maximum measured plasma concentrationaSingle-dose viloxazine ER (400 mg)bSingle-dose viloxazine ER (200 mg)cMPRs are adjusted on the basis of the molecular weights of viloxazine (237) and 5-HVLX-gluc (429) Summary of 5-HVLX-gluc plasma pharmacokinetic parameters All data reported as mean ± SD (CV), except Tmax, which is reported as median (range) P values for Tmax and t1/2 are from nonparametric Wilcoxon rank-sum tests on untransformed parameter values P values for Cmax, AUC0–t, and AUCinf are from analysis of variance analyses of log-transformed parameter values 5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, h hours, HI hepatic impairment, MPR metabolite-to-parent ratio, SD standard deviation, t1/2 terminal elimination half-life, Tmax time of the maximum measured plasma concentration aSingle-dose viloxazine ER (400 mg) bSingle-dose viloxazine ER (200 mg) cMPRs are adjusted on the basis of the molecular weights of viloxazine (237) and 5-HVLX-gluc (429) 5-HVLX-gluc concentration–time profiles. 5-HVLX-gluc concentration–time profiles after administration of viloxazine ER in participants with mild, moderate, or severe HI (groups 1, 2, and 3) and healthy matches (groups 4a, 4b, and 4c) on linear (A, C, E) and semi-logarithmic (B, D, F) scales. Participants with mild or moderate HI and healthy matches received viloxazine ER 400 mg. Participants with severe HI and healthy matches received viloxazine ER 200 mg. Means ± standard deviation. 5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, ER extended release, HI hepatic impairment Table 45-HVLX-gluc relative bioavailabilityHIHealthy matchRatio (90% CI)dCVCmax Milda2.251.95115.55% (82.73–161.39)39.3% Moderateb1.171.5376.23% (56.44–102.96)35.2% Severec0.360.7350.12% (38.89–64.61)28.2%AUC0–t Milda50.344.6112.85% (82.15–155.03)37.3% Moderateb28.234.781.32% (60.09–110.06)35.4% Severec11.416.768.27% (53.65–86.87)26.8%AUCinf Milda51.045.0113.33% (82.56–155.55)37.2% Moderateb28.835.381.47% (59.51–111.52)36.8% Severec11.816.970.02% (54.79–89.48)27.3%All values are the geometric means, based on least-squares means of log-transformed parameter values5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, CI confidence interval, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, HI hepatic impairmentaCompares group 1 (mild HI) versus matched controls, single-dose viloxazine ER (400 mg)bCompares group 2 (moderate HI) versus matched controls, single-dose viloxazine ER (400 mg)cCompares group 3 (severe HI) versus matched controls, single-dose viloxazine ER (200 mg)dRatio = HI/healthy matches (%), with 90% CIs 5-HVLX-gluc relative bioavailability All values are the geometric means, based on least-squares means of log-transformed parameter values 5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, CI confidence interval, Cmax maximum measured plasma concentration, CV coefficient of variation, ER extended release, HI hepatic impairment aCompares group 1 (mild HI) versus matched controls, single-dose viloxazine ER (400 mg) bCompares group 2 (moderate HI) versus matched controls, single-dose viloxazine ER (400 mg) cCompares group 3 (severe HI) versus matched controls, single-dose viloxazine ER (200 mg) dRatio = HI/healthy matches (%), with 90% CIs Relative bioavailability of plasma viloxazine 5-HVLX-gluc. Ratio (%) of the relative bioavailability of 5-HVLX-gluc in plasma for PK parameters Cmax (A), AUC0–t (B), and AUCinf (C; geometric means ± 90% confidence intervals, based on least-squares means of log-transformed parameter values). 5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, PK pharmacokinetic Box Plots for Viloxazine and 5-HVLX-gluc Exposure Box plots comparing Cmax, AUC0–t, and AUCinf between mild, moderate, and severe hepatic impairment groups and their matched control group are shown in Fig. 5. Plots for participants with severe hepatic impairment and matched healthy controls (who received 200 mg/day viloxazine ER) were adjusted to reflect a 400-mg viloxazine ER dose for comparison purposes. Dose-adjusted box plots for viloxazine and 5-HVLX-gluc. Box plots for viloxazine (A–C) and 5-HVLX-gluc (D–F) analytes comparing PK parameters Cmax, AUC0–t, and AUCinf across groups (1, 2, 3, 4a, 4b, and 4c). Groups 3 and 4c were dose-adjusted to the 400-mg dose (group 1 = mild HI [400 mg]; group 2 = moderate HI [400 mg]; group 3 = severe HI [200 mg]; group 4a = matched controls to mild HI [400 mg]; group 4b = matched controls to moderate HI [400 mg]; group 4c = matched controls to severe HI [200 mg]; dashed line = median; solid line = average; box = upper and lower quartiles; whiskers = 5% and 95% percentiles; circle = outliers). 5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUC0–t area under the concentration–time curve from time 0 to the last measurable time, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, HI hepatic impairment, PK pharmacokinetic Relationship Between Viloxazine ER Exposure and Hepatic Impairment Indicators Viloxazine Cmax did not show significant correlation with any of the tested hepatic impairment indicators (albumin, bilirubin, prothrombin time, and INR) or overall Child–Pugh score (Table 5). Viloxazine AUCinf showed only a weak correlation with the above hepatic impairment indicators that was statistically significant for all but bilirubin and the overall Child–Pugh score (Table 5 and Supplementary Fig. S1). The lack of statistically significant correlation between viloxazine AUCinf with the Child–Pugh score, despite significant correlation with Child–Pugh component indicators, may be explained by the omission of healthy controls from this correlation because they did not have a Child–Pugh score. When analyses were repeated with participants in the healthy control groups assigned an artificial Child–Pugh ranking score of 5 (to indicate normal hepatic function for purposes of analysis), the correlation became statistically significant between viloxazine AUCinf and Child–Pugh score (p value = 0.0171) but remained weak (R2 = 0.1200). Table 5Correlation between viloxazine and 5-HVLX-gluc pharmacokinetic parameters and hepatic impairment indicatorsViloxazine5-HVLX-glucSlopeP value of slopeR2SlopeP value of slopeR2Cmax versus Child–Pugh scorea,b− 0.0540.40570.0316− 0.2140.00010.4956Cmax versus albumin0.09310.60950.00580.58710.00220.1903Cmax versus bilirubin− 0.0560.57770.0069− 0.3440.00110.2132Cmax versus prothrombin time0.01090.76700.002− 0.1260.00100.2169Cmax versus INR0.10830.81510.0012− 1.2850.00900.142AUCinf versus Child–Pugh scorea,c2.8970.16580.0854− 3.6460.00140.3763AUCinf versus albumin− 13.210.02630.10498.85890.02590.1055AUCinf versus bilirubin5.52450.09750.0598− 5.3720.01410.1265AUCinf versus prothrombin time3.08010.00920.1415− 1.8750.01850.1172AUCinf versus INR37.8380.01140.134− 16.610.10400.05775-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, INR international normalized ratioaFor regression analyses of Child–Pugh scores, only individuals with hepatic impairment were included in the prespecified analysis (because healthy controls did not have a Child–Pugh score, they were not included in this analysis)bWhen healthy control participants were assigned a Child–Pugh ranking score of 5 (indicating no hepatic impairment for purposes of analysis), the slope was − 0.0207 (p = 0.6151), R2 = 0.0057 for viloxazine, and − 0.1635 (p < 0.0001), R2 = 0.2886 for 5-HVLX-gluccWhen healthy control participants were assigned a Child–Pugh ranking score of 5 (indicating no hepatic impairment for purposes of analysis), the slope was 3.1954 (p = 0.0171), R2 = 0.1200 for viloxazine, and − 2.7156 (p = 0.0020), R2 = 0.1937 for 5-HVLX-gluc Correlation between viloxazine and 5-HVLX-gluc pharmacokinetic parameters and hepatic impairment indicators 5-HVLX-gluc 5-hydroxy-viloxazine glucuronide, AUCinf area under the concentration–time curve from time 0 to infinity, Cmax maximum measured plasma concentration, INR international normalized ratio aFor regression analyses of Child–Pugh scores, only individuals with hepatic impairment were included in the prespecified analysis (because healthy controls did not have a Child–Pugh score, they were not included in this analysis) bWhen healthy control participants were assigned a Child–Pugh ranking score of 5 (indicating no hepatic impairment for purposes of analysis), the slope was − 0.0207 (p = 0.6151), R2 = 0.0057 for viloxazine, and − 0.1635 (p < 0.0001), R2 = 0.2886 for 5-HVLX-gluc cWhen healthy control participants were assigned a Child–Pugh ranking score of 5 (indicating no hepatic impairment for purposes of analysis), the slope was 3.1954 (p = 0.0171), R2 = 0.1200 for viloxazine, and − 2.7156 (p = 0.0020), R2 = 0.1937 for 5-HVLX-gluc Relationship Between 5-HVLX-gluc Exposure and Hepatic Impairment Indicators Stronger but inverse correlations were observed between hepatic impairment indicators and 5-HVLX-gluc exposure (greater hepatic impairment associated with lower metabolite concentrations), with all correlations showing statistical significance for Cmax, and all correlations with the exception of INR showing statistical significance for AUCinf (Table 5 and Supplementary Fig. S1). For the Child–Pugh score, adjusted regression coefficients were R2 = 0.4956 (p = 0.0001) for Cmax and R2 = 0.3763 (p = 0.0014) for AUCinf. Safety Only 6 (13.3%) of the 45 participants (3 with mild hepatic impairment and 3 healthy controls) reported any treatment-emergent adverse events, all of which were assessed as mild (4 participants) or moderate (2 participants) in severity. Adverse events reported by more than one participant included only headache (n = 3; one with mild hepatic impairment, two in healthy controls) and somnolence (n = 2; one with mild hepatic impairment, one healthy control). A list of adverse events by participant is presented in Table 6. No adverse events were categorized as serious, and none led to participant withdrawal. There were no remarkable changes in clinical laboratory test results, and ECGs, vital signs, or physical examination parameters. Table 6Treatment-emergent adverse eventsParticipantHepatic impairmentaViloxazine ER dosebReported AE(s)cSeverityRelationship to study medicationdTime of onseteAE durationf1Mild400 mgSomnolenceMildPossibly1 h 27 min8 h2Mild400 mgDizzinessMildPossibly2 h 57 min11 min3Mild400 mgHeadacheParanasal sinus discomfortMyalgiaMildMildModeratePossiblyPossiblyPossibly22 h 3 min22 h 3 min2 days 5 h 53 min1 day 1 h 10 min1 day 6 h 50 min3 days 6 h4None, healthy control400 mgSomnolenceMildDefinitely1 h 30 min1 h 45 min5None, healthy control400 mgHeadacheMildPossibly4 h 1 min18 h 59 min6None, healthy control200 mgDyspepsiaConstipationHeadacheMildMildModeratePossiblyPossiblyPossibly6 h 20 min10 h 20 min1 day 1 h 50 min1 day 15 h 40 min1 day 11 h 40 min1 day 21 h 40 minAE adverse event, ER extended release, h hours, min minutes, MedDRA® Medical Dictionary for Regulatory ActivitiesaBased on Child–Pugh classbGiven as single dose on day 1cMedDRA® (version 22.1) preferred termdRelationship of AE to study medication was assessed by the investigator as definitely, probably, possibly, unlikely, or not related to study medicationeTime of AE onset in days, h, and min following viloxazine ER administrationfTime to AE resolution in days, h, and min following AE onset Treatment-emergent adverse events Headache Paranasal sinus discomfort Myalgia Mild Mild Moderate Possibly Possibly Possibly 22 h 3 min 22 h 3 min 2 days 5 h 53 min 1 day 1 h 10 min 1 day 6 h 50 min 3 days 6 h Dyspepsia Constipation Headache Mild Mild Moderate Possibly Possibly Possibly 6 h 20 min 10 h 20 min 1 day 1 h 50 min 1 day 15 h 40 min 1 day 11 h 40 min 1 day 21 h 40 min AE adverse event, ER extended release, h hours, min minutes, MedDRA® Medical Dictionary for Regulatory Activities aBased on Child–Pugh class bGiven as single dose on day 1 cMedDRA® (version 22.1) preferred term dRelationship of AE to study medication was assessed by the investigator as definitely, probably, possibly, unlikely, or not related to study medication eTime of AE onset in days, h, and min following viloxazine ER administration fTime to AE resolution in days, h, and min following AE onset Discussion In this study, hepatic impairment showed minimal impact on the relative bioavailability of viloxazine after administration of a single oral dose (200 or 400 mg) of viloxazine ER. The relative bioavailability of viloxazine ER among individuals with mild, moderate, or severe hepatic impairment remained within 25% of concentrations observed in matched healthy controls (based on geometric mean exposure ratios for Cmax and AUC), despite a prolonged t1/2 in participants with moderate and severe hepatic impairment relative to healthy controls (reflecting some prolongation of apparent clearance of viloxazine, which may be due to reduced systemic clearance). Additionally, the overall magnitudes of change in drug exposure across the spectrum of mild-to-severe hepatic impairment, even at the upper confidence interval bounds, remained below the ≥ 2-fold threshold of exposure variability that would typically necessitate a dose adjustment based on the FDA’s guidance on pharmacokinetics in patients with impaired hepatic function [13]. Given viloxazine’s wide safety margin, the substantial variability in exposure across levels of hepatic impairment, and the absence of clear evidence that the observed pharmacokinetic differences translate into clinically meaningful effects, blanket dosage-adjustment recommendations are not warranted. Conversely, increasing severity of hepatic impairment did reduce exposure to viloxazine’s (presumed inactive) primary 5-HVLX-gluc metabolite, suggesting reduced metabolite formation with increasing severity of hepatic damage. Still, the geometric mean ratios for the primary metabolite remained within 25% of matched healthy controls for mild and moderate hepatic impairment and were ~ 50% (Cmax) and ~ 70% (AUC) of controls for severe hepatic impairment (Fig. 4). The decrease in primary metabolite concentrations but lack of corresponding increase in parent drug concentrations with severity of hepatic insufficiency suggests that other elimination pathways (perhaps greater renal elimination of parent drug) may have compensated to some extent for varied degrees of liver dysfunction. Regression analyses were consistent with these findings, showing no clear relationship between hepatic function indicators and viloxazine ER exposure (AUC and Cmax) but stronger relationships between these indicators and 5-HVLX-gluc metabolite exposure. Notably, there was no strong association between Child–Pugh score and viloxazine ER Cmax or AUC, but a significant relationship between Child–Pugh score and the 5-HVLX-gluc metabolite, where it explained ~ 40% of model variance for AUC and ~ 50% of the variance for Cmax (Supplementary Fig. S1). Individuals with hepatic impairment are vulnerable to alterations in drug absorption, distribution, metabolism, and biliary excretion resulting from liver injury [14]. Hepatic impairment can additionally lead to decreased renal function, which can also affect drug elimination [15]. Altered pharmacodynamics are also possible, with potential effects on drug efficacy and risk for adverse events, which may require dose adjustment. Although this study suggests minimal impact of mild-to-severe hepatic impairment on viloxazine relative bioavailability, the single-dose nature of the study design and conduct in individuals without ADHD limits interpretation of safety findings and does not allow for evaluation of potential impacts on efficacy. Overall, the study did not identify safety concerns; no severe or serious adverse events were reported. Only six participants (three of whom were healthy controls) experienced any adverse events, which were largely mild in severity (Table 6). Additionally, no patient with moderate or severe hepatic impairment reported any adverse event within the confines of this study. Although these findings are reassuring, the study’s single-dose design, small population, and inclusion of generally healthy participants with hepatic impairment limit the conclusions that can be drawn about safety during repeated dosing. These results support the continued investigation of viloxazine ER in populations with varying degrees of hepatic impairment, with appropriate clinical monitoring. Viloxazine (studied in both ER and immediate-release formulations) has shown a relatively wide safety margin at higher doses, indicating that more substantial viloxazine exposures than the small changes observed in severe hepatic impairment are unlikely to lead to major complications or toxicity events [16]. For example, supratherapeutic doses of viloxazine ER (up to 1800 mg) have been evaluated in adults in phase 1 studies without remarkable deviations in commonly reported adverse events or observed effects on cardiac repolarization and other ECG parameters [9, 10, 17]. In literature-reported cases of overdose, patients have made full recoveries after ingesting doses as high as 1.5–2 g [5]. In ADHD, pediatric and adult phase 2 and 3 double-blind trials, and multi-year, extended open-label trials have continued to demonstrate acceptable safety and tolerability at doses up to 600 mg/day [18–22]. Although viloxazine ER is often compared with atomoxetine, another nonstimulant ADHD medication thought to work by inhibiting norepinephrine transporters, viloxazine has a different chemical structure, resulting in differences in pharmacologic profile, pharmacodynamics, pharmacokinetics, and metabolic clearance pathways. Unlike viloxazine, atomoxetine is highly bound to plasma albumin and is more dependent on CYP2D6 metabolism, showing a tenfold decrease in clearance in CYP2D6 poor metabolizers. This is relevant to hepatic insufficiency in that CYP2D6 activity may be reduced in moderate and severe hepatic impairment. Additionally, a greater percentage of atomoxetine is eliminated in the feces (17%) as conjugated metabolites compared with viloxazine (< 1%), potentially indicating greater biliary excretion. Consistent with these differences, atomoxetine showed significant reductions in total body clearance in moderate and severe hepatic impairment of 50% and 75%, respectively, increases in drug exposure (AUC) of fourfold and tenfold, respectively, increases in plasma half-life of two- and fourfold, respectively, and reduced plasma protein binding from 98.7 to 96.5% that required dosage adjustment in moderate and severe hepatic impairment (no adjustments are currently stipulated in viloxazine ER prescribing information). From a safety perspective, atomoxetine has been associated with rare cases of hepatotoxicity with severe liver injury (accompanied by jaundice, elevated bilirubin, and markedly increased hepatic enzymes) thought to be due to reactive metabolites. Viloxazine has not been associated with hepatotoxicity or liver injury. Limitations to our study include small sample size, though this is typical for pharmacokinetic studies in hepatic impairment, administration of only a single dose of viloxazine ER, and lack of inclusion of higher doses of viloxazine, particularly in patients with severe hepatic impairment. As alternative elimination pathways (e.g., increased renal clearance of parent drug) may compensate for hepatic dysfunction, these findings may not generalize to individuals with poor renal function. Conclusions In this study, mild, moderate, and severe hepatic impairment showed minimal effects on the relative bioavailability of viloxazine ER. There were no safety signals identified in this study on the basis of evaluation of safety data (adverse events, vital signs, clinical laboratory tests, and ECGs). Results suggest that a carefully considered treatment plan with viloxazine ER in individuals with hepatic impairment is unlikely to result in clinically meaningful variability in drug exposure. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (PDF 227 KB)